Bayesian dose escalation with overdose and underdose control utilizing all toxicities in phase I/II clinical trials

Could not fetch data.

Cites Work

Unifying CRM and EWOC designs for phase I cancer clinical trials
Estimating Regression Models with Multiplicative Heteroscedasticity
Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents
A Bayesian seamless phase I–II trial design with two stages for cancer clinical trials with drug combinations
A flexible design for advanced Phase I/II clinical trials with continuous efficacy endpoints
Multivariate Correlation Models with Mixed Discrete and Continuous Variables

This page was built for publication: Bayesian dose escalation with overdose and underdose control utilizing all toxicities in phase I/II clinical trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6625365)